[Increase in the pulmonary toxicity of bleomycin caused by the FiO2]. 1992

B de la Quintana, and M J Arribas, and A Carrera, and E Pascual, and M García-Guiral, and J I Lora-Tamayo

UI MeSH Term Description Entries
D008297 Male Males
D010100 Oxygen An element with atomic symbol O, atomic number 8, and atomic weight [15.99903; 15.99977]. It is the most abundant element on earth and essential for respiration. Dioxygen,Oxygen-16,Oxygen 16
D011658 Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death. Alveolitis, Fibrosing,Idiopathic Diffuse Interstitial Pulmonary Fibrosis,Fibroses, Pulmonary,Fibrosis, Pulmonary,Pulmonary Fibroses,Alveolitides, Fibrosing,Fibrosing Alveolitides,Fibrosing Alveolitis
D001761 Bleomycin A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. BLEO-cell,Blanoxan,Blenoxane,Bleolem,Bleomicina,Bleomycin A(2),Bleomycin A2,Bleomycin B(2),Bleomycin B2,Bleomycin Sulfate,Bleomycins,Bleomycinum Mack,Bléomycine Bellon,BLEO cell,BLEOcell,Bellon, Bléomycine,Mack, Bleomycinum,Sulfate, Bleomycin
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012306 Risk The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome. Relative Risk,Relative Risks,Risk, Relative,Risks,Risks, Relative

Related Publications

B de la Quintana, and M J Arribas, and A Carrera, and E Pascual, and M García-Guiral, and J I Lora-Tamayo
January 1976, Therapie,
B de la Quintana, and M J Arribas, and A Carrera, and E Pascual, and M García-Guiral, and J I Lora-Tamayo
April 1973, Annals of internal medicine,
B de la Quintana, and M J Arribas, and A Carrera, and E Pascual, and M García-Guiral, and J I Lora-Tamayo
April 1973, Chest,
B de la Quintana, and M J Arribas, and A Carrera, and E Pascual, and M García-Guiral, and J I Lora-Tamayo
August 1976, Environmental health perspectives,
B de la Quintana, and M J Arribas, and A Carrera, and E Pascual, and M García-Guiral, and J I Lora-Tamayo
July 1994, Lancet (London, England),
B de la Quintana, and M J Arribas, and A Carrera, and E Pascual, and M García-Guiral, and J I Lora-Tamayo
March 1990, Clinics in chest medicine,
B de la Quintana, and M J Arribas, and A Carrera, and E Pascual, and M García-Guiral, and J I Lora-Tamayo
January 1985, The Netherlands journal of medicine,
B de la Quintana, and M J Arribas, and A Carrera, and E Pascual, and M García-Guiral, and J I Lora-Tamayo
January 1973, Radiology,
B de la Quintana, and M J Arribas, and A Carrera, and E Pascual, and M García-Guiral, and J I Lora-Tamayo
January 1982, Revista clinica espanola,
B de la Quintana, and M J Arribas, and A Carrera, and E Pascual, and M García-Guiral, and J I Lora-Tamayo
November 1987, Gynecologic oncology,
Copied contents to your clipboard!